The Lancet Oncology
@TheLancetOncol
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=51.1
ID:50265238
http://www.thelancet.com/journals/lanonc 24-06-2009 09:52:31
10,0K Tweets
57,9K Followers
421 Following
Also in the May issue:
Results from ENZA-p:
177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant #prostatecancer : an open-label, multicentre, randomised, phase 2 trial thelancet.com/journals/lanonโฆ
Iโm hosting a webinar on abstract writing for the Conference on Liver Disease in Africa 2024 on Thursday; registration open at virology.eventsair.com/solda/webinar-โฆ
#LiverTwitter #SOLDA Solda - Society on Liver Disease in Africa
๐ข We are pleased to announce the launch of our Series: '๐๐ฑ๐ฑ๐ฟ๐ฒ๐๐๐ถ๐ป๐ด ๐บ๐ถ๐ด๐ฟ๐ฎ๐๐ถ๐ผ๐ป ๐ฎ๐ป๐ฑ ๐ต๐ฒ๐ฎ๐น๐๐ต ๐ถ๐ป๐ฒ๐พ๐๐ถ๐๐ ๐ถ๐ป ๐๐๐ฟ๐ผ๐ฝ๐ฒ' on May 28th in ๐๐ฒ๐ป๐ฒ๐๐ฎ. Join us if you can.
Register here: tinyurl.com/2pt5s8f2
New research - Ruco et al - Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study
thelancet.com/journals/langaโฆ
#GITwitter #CRCSM #ColorectalCancer Nancy Baxter MD PhD Arlinda R.
ICYMI:
Results from the multicentre, single-arm, phase 2 TRAIN-3 study: MRI-guided optimisation of neoadjuvant chemotherapy duration in stage IIโIII HER2-positive #breastcancer thelancet.com/journals/lanonโฆ
Editor-in-Chief Rob Brierley will be at the 1st African Viral Hepatitis Convention, co-convened with #IHPBA24 in Cape Town, this week; details below if you wish to get in touch
Learn about our scope & impact here: hubs.li/Q01CYmHX0
#IHPBA2024 #AVHC #LiverTwitter #NoHep
Online First:
Effect of #ProjectOrbis participation by the Swiss regulator Swissmedic on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis
#cancerdrugs
thelancet.com/journals/lanonโฆ
Also Online First:
#Overallsurvival benefits of #cancerdrugs initially approved by the US Food and Drug Administration U.S. FDA on the basis of immature survival data: a retrospective analysis
thelancet.com/journals/lanonโฆ
Out in The Lancet Oncology, the latest analysis by our colleague Dr Anita Wolfer head of the breast cancer clinic HUG and colleagues at Swissmedic - Project Orbis a collaborative parallel-review programme launched by U.S. FDA in 2019 to expedite patient access to cancer drugs.
Online First:
Results from KEYNOTE-057:
#Pembrolizumab monotherapy for high-risk non-muscle-invasive #bladdercancer without carcinoma in situ and unresponsive to BCG: a single-arm, multicentre, phase 2 trial
#gusm
thelancet.com/journals/lanonโฆ